June 15, 2020 / 11:28 AM / 2 months ago

BRIEF-Brickell Biotech Announces Positive Phase 3 Pivotal Study Results For Sofpironium Bromide In Japan

June 15 (Reuters) - Brickell Biotech Inc:

* BRICKELL BIOTECH ANNOUNCES POSITIVE PHASE 3 PIVOTAL STUDY RESULTS FOR SOFPIRONIUM BROMIDE IN JAPAN RELEASED BY DEVELOPMENT PARTNER, KAKEN PHARMACEUTICAL

* BRICKELL BIOTECH INC - ALL PRIMARY AND SECONDARY ENDPOINTS OF STUDY WERE MET AND ACHIEVED STATISTICAL SIGNIFICANCE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below